Peptide receptor radionuclide therapy as neoadjuvant therapy for resectable or potentially resectable pancreatic neuroendocrine neoplasms

Surgery ◽  
2018 ◽  
Vol 163 (4) ◽  
pp. 761-767 ◽  
Author(s):  
Stefano Partelli ◽  
Emilio Bertani ◽  
Mirco Bartolomei ◽  
Carolina Perali ◽  
Francesca Muffatti ◽  
...  
Keyword(s):  
Neoadjuvant Therapy ◽  
Radionuclide Therapy ◽  
Peptide Receptor Radionuclide Therapy ◽  
Neuroendocrine Neoplasms ◽  
Pancreatic Neuroendocrine Neoplasms ◽  
Peptide Receptor

scholarly journals Value of Peptide Receptor Radionuclide Therapy as Neoadjuvant Treatment in the Management of Primary Inoperable Neuroendocrine Tumors

2021 ◽  
Vol 11 ◽  
Author(s):  
Marta Opalińska ◽  
Anna Sowa-Staszczak ◽  
Anna Grochowska ◽  
Helena Olearska ◽  
Alicja Hubalewska-Dydejczyk
Keyword(s):  
Neoadjuvant Therapy ◽  
Neuroendocrine Tumors ◽  
Radionuclide Therapy ◽  
Neoadjuvant Treatment ◽  
Peptide Receptor Radionuclide Therapy ◽  
Tumor Burden ◽  
Neuroendocrine Neoplasms ◽  
First Line ◽  
Peptide Receptor ◽  
Radical Treatment

IntroductionNeuroendocrine neoplasms including neuroendocrine tumors (NETs) are often diagnosed as primary disseminated or inoperable. In those cases, systemic extensive therapy is necessary, but radical treatment is unlikely. As described in the literature, in some selected cases, peptide receptor radionuclide therapy (PRRT) may be used as a first-line/neoadjuvant therapy that allows further successful surgery. Such treatment may enable a reduction of total tumor burden or allow a radical treatment which improves the final outcomes.AimThis study aims to assess whether neoadjuvant PRRT could be a treatment option for patients with initially unresectable NETs.MethodsAmong the group of 114 patients treated with PRRT between the years 2005 and 2020, in 32 cases, it was the first-line therapy, mainly due to massive disease burden at the time of diagnosis. Among them, nine patients received PRRT as the first-line treatment due to the primary inoperable tumors with the intention of preoperative reduction of the tumor size in order to allow for a surgical treatment.ResultsNeoadjuvant PRRT enabled surgery in four out of nine (45%) patients. Finally, in two out of four cases, the goal (radical surgery) has been achieved.ConclusionPRRT may be considered not only as a palliative but also as a neoadjuvant therapy in advanced, somatostatin-positive NETs that were initially inoperable.

Sign in / Sign up

Export Citation Format

Share Document